Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

109,684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study.
Yin Y, Jia M, Li Y, Zhao W, Chen S, Huo P, Zhao Q, Yu L, Wang C, Ma Y, Wang M, Zhang J. Yin Y, et al. Among authors: wang m, wang c. Travel Med Infect Dis. 2024 Dec 20;63:102792. doi: 10.1016/j.tmaid.2024.102792. Online ahead of print. Travel Med Infect Dis. 2024. PMID: 39710015 Free article.
Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial.
Liu X, Li Y, Li J, Zhou J, Guo J, Pu Y, Jiang Y, Zhou Y, Jiang Z, Shu Q, Wang C, Wang J, Zhao Y, Zhao W, Wang H, Wei J, Yu H, Gao J, Li X. Liu X, et al. Among authors: wang h, wang j, wang c. Int J Infect Dis. 2023 Sep;134:53-62. doi: 10.1016/j.ijid.2023.05.017. Epub 2023 May 19. Int J Infect Dis. 2023. PMID: 37211270 Free article. Clinical Trial.
109,684 results
You have reached the last available page of results. Please see the User Guide for more information.